바이오모아 (BioMoa) — ADC · Antibody

9268프로그램 35FDA 승인

0오늘 방문

572누적 방문

8122갱신 대기 S–CData Tier S/A/B차세대 1068HER2 breast 5456Antibody 2744CGT →Psoriasis →NSCLC 35FDA 승인

피드 Data Tier 차세대

최근 활동

RSS →

ADCBiologicstaleFBD Biologics LimitedPhase 2

HCB101 (HCB101)

Solid Cancer · Solid Cancer

#SolidCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 4상태 RECRUITING

AntibodystaleBeiGenePhase 1

atezolizumab (Tecentriq, Tislelizumab，atezolizumab or sugemalimab)

NSCLC · NSCLC

#NSCLC#Antibody#Phase1#항체#면역항체+2

임상시험 4상태 RECRUITING

AntibodyJanssenPhase 2

Amivantamab + FOLFIRI (Amivantamab + FOLFIRI)

RAS/BRAF Wild-type Advanced Colorectal Cancer Patients · RAS/BRAF Wild-type Advanced Colorectal C

#RASBRAFWild-typeAdvancedColorect#Antibody#Phase2#항체#면역항체+4

임상시험 4상태 RECRUITING

CGTBiologicThe Affiliated Hospital of Xuzh…Phase 2

Anti-CD56 CAR T (Anti-CD56 CAR T)

Extranodal NK T Cell Lymphoma; NK-Cell Leukemia · Extranodal NK T Cell Lymphoma

#ExtranodalNKTCellLymphoma#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 4상태 RECRUITING

ADCBiologicstaleQuantumLeap Healthcare Collabor…Phase 2

Amcenestrant + Letrozole (Amcenestrant + Letrozole)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

효능 ORR 42.3%임상시험 4상태 RECRUITING

CGTBiologicstaleElvira UmyarovaPhase 1

Universal Donor Expanded TGF-beta-imprinted NK Cells (Universal Donor Expanded TGF-beta-imprinted NK Cells)

Recurrent Multiple Myeloma; Refractory Multiple Myeloma · HER2

#HER2#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 4상태 ACTIVE

ADCBiologicstaleRochePhase 2

trastuzumab (Herceptin, Patritumab and Trastuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

임상시험 4상태 RECRUITING

AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, SD-101 + Pembrolizumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4

효능 ORR 3.2%임상시험 4상태 RECRUITING

CGTBiologicstaleChongqing Precision Biotech Co.…Phase 2

CD123 targeted CAR-NK cells (CD123 targeted CAR-NK cells)

Acute Myeloid Leukemia; Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4

임상시험 4상태 RECRUITING

ADCBiologicstaleShanghai Yuansong Biotechnology…Phase 2

YSCH-01 (YSCH-01)

Recurrent Glioblastoma · Rare Malignant Neoplasm

#RareMalignantNeoplasm#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

임상시험 4상태 RECRUITING

CGTBiologicstaleAllife Medical Science and Tech…Phase 1

pd-1 and DC-NK cells (pd-1 and DC-NK cells)

Solid Tumor · PD-1

#PD-1#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 4상태 ACTIVE

CGTBiologicFrontera TherapeuticsPhase 2

FT-003 (FT-003)

Diabetic Macular Edema · Neovascular Age-related Macular Degenera

#NeovascularAge-relatedMacularDeg#CGT#Phase2#세포유전치료#CAR-T+4

임상시험 4상태 RECRUITING

CGTBiologicStichting Hemato-Oncologie voor…Phase 2

ARI-0001 (ARI-0001)

NHL; DLBCL - Diffuse Large B Cell Lymphoma · NHL

#NHL#CGT#Phase2#세포유전치료#CAR-T+4

임상시험 4상태 RECRUITING

CGTBiologicstaleChina Immunotech (Beijing) Biot…Phase 1

CMV-TCR-T cells (CMV-TCR-T cells)

CMV Infection After Allogenic HSCT · Allogeneic Hematopoietic Stem Cell Trans

#AllogeneicHematopoieticStemCellT#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 4상태 ACTIVE

CGTBiologicstaleNational Cancer Institute (NCI)Phase 1

KRAS TCR-Transduced PBL (KRAS TCR-Transduced PBL)

Metastatic Solid Cancers; Colorectal Cancer · Gastrointestinal Carcinoma

#GastrointestinalCarcinoma#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 4상태 RECRUITING

ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

5-hydroxytryptamine subtype 3 receptor antagonist (5-hydroxytryptamine subtype 3 receptor antagonist)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

임상시험 4상태 RECRUITING

CGTBiologicYake Biotechnology Ltd.Phase 1

APRIL CAR-T cells (APRIL CAR-T cells)

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5

임상시험 4상태 RECRUITING

ADCBiologicstaleTelix Pharmaceuticals (Innovati…Phase 1

177Lu-DOTA-TLX591 (177Lu-DOTA-TLX591)

Metastatic Prostate Cancer · Metastatic Prostate Cancer

#MetastaticProstateCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1

임상시험 4상태 ACTIVE

ADCBiologicstaleMinghui Pharmaceutical (Hangzho…Phase 2

MHB036C (MHB036C)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 4상태 RECRUITING

CGTBiologicstaleiCell Gene TherapeuticsPhase 1

CD7CAR T cells (CD7CAR T cells)

Relapsed/Refractory, High Risk Hematologic Malignancies; T-ALL/Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5

임상시험 4상태 ACTIVE

CGTBiologicSara V. LatorrePhase 2

ARI-0001 cells (ARI-0001 cells)

Acute Lymphoid Leukemia · Acute Lymphoid Leukemia

#AcuteLymphoidLeukemia#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 4상태 RECRUITING

CGTBiologicstaleCity of Hope Medical CenterPhase 1

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes)

B Acute Lymphoblastic Leukemia; Recurrent Acute Lymphoblastic Leukemia · EGFR

#EGFR#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 4상태 RECRUITING

CGTBiologicPolina StepenskyPhase 2

HBI0101 CART (HBI0101 CART)

Multiple Myeloma, Refractory to Standard Treatment; Multiple Myeloma, Relapsed · Systemic Sclerosis (SSc)

#SystemicSclerosisSSc#CGT#Phase2#세포유전치료#CAR-T+5

임상시험 4상태 RECRUITING

CGTBiologicstaleShenzhen Genocury Biotech Co., …Preclinical

CD19/BCMA-targeted CAR-T lentiviral vector drug (CD19/BCMA-targeted CAR-T lentiviral vector drug)

Autoimmune Diseases · CD19

#CD19#CGT#Preclinical#세포유전치료#CAR-T+3

임상시험 4상태 RECRUITING

AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab [TECENTRIQ])

Neoplasms · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+3

효능 ORR 33.33%임상시험 4상태 ACTIVE

45 / 167 페이지

← 이전 다음 →

전체 9,268개 프로그램 보기

갱신 기록 없음 · 14일 주기 · 방문 0 / 572

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

HCB101 (HCB101)

atezolizumab (Tecentriq, Tislelizumab，atezolizumab or sugemalimab)

Amivantamab + FOLFIRI (Amivantamab + FOLFIRI)

Anti-CD56 CAR T (Anti-CD56 CAR T)

Amcenestrant + Letrozole (Amcenestrant + Letrozole)

Universal Donor Expanded TGF-beta-imprinted NK Cells (Universal Donor Expanded TGF-beta-imprinted NK Cells)

trastuzumab (Herceptin, Patritumab and Trastuzumab)

pembrolizumab (Keytruda, SD-101 + Pembrolizumab)

CD123 targeted CAR-NK cells (CD123 targeted CAR-NK cells)

YSCH-01 (YSCH-01)

pd-1 and DC-NK cells (pd-1 and DC-NK cells)

FT-003 (FT-003)

ARI-0001 (ARI-0001)

CMV-TCR-T cells (CMV-TCR-T cells)

KRAS TCR-Transduced PBL (KRAS TCR-Transduced PBL)

5-hydroxytryptamine subtype 3 receptor antagonist (5-hydroxytryptamine subtype 3 receptor antagonist)

APRIL CAR-T cells (APRIL CAR-T cells)

177Lu-DOTA-TLX591 (177Lu-DOTA-TLX591)

MHB036C (MHB036C)

CD7CAR T cells (CD7CAR T cells)

ARI-0001 cells (ARI-0001 cells)

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes)

HBI0101 CART (HBI0101 CART)

CD19/BCMA-targeted CAR-T lentiviral vector drug (CD19/BCMA-targeted CAR-T lentiviral vector drug)

atezolizumab (Tecentriq, Atezolizumab [TECENTRIQ])

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

HCB101 (HCB101)

atezolizumab (Tecentriq, Tislelizumab，atezolizumab or sugemalimab)

Amivantamab + FOLFIRI (Amivantamab + FOLFIRI)

Anti-CD56 CAR T (Anti-CD56 CAR T)

Amcenestrant + Letrozole (Amcenestrant + Letrozole)

Universal Donor Expanded TGF-beta-imprinted NK Cells (Universal Donor Expanded TGF-beta-imprinted NK Cells)

trastuzumab (Herceptin, Patritumab and Trastuzumab)

pembrolizumab (Keytruda, SD-101 + Pembrolizumab)

CD123 targeted CAR-NK cells (CD123 targeted CAR-NK cells)

YSCH-01 (YSCH-01)

pd-1 and DC-NK cells (pd-1 and DC-NK cells)

FT-003 (FT-003)

ARI-0001 (ARI-0001)

CMV-TCR-T cells (CMV-TCR-T cells)

KRAS TCR-Transduced PBL (KRAS TCR-Transduced PBL)

5-hydroxytryptamine subtype 3 receptor antagonist (5-hydroxytryptamine subtype 3 receptor antagonist)

APRIL CAR-T cells (APRIL CAR-T cells)

177Lu-DOTA-TLX591 (177Lu-DOTA-TLX591)

MHB036C (MHB036C)

CD7CAR T cells (CD7CAR T cells)

ARI-0001 cells (ARI-0001 cells)

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes)

HBI0101 CART (HBI0101 CART)

CD19/BCMA-targeted CAR-T lentiviral vector drug (CD19/BCMA-targeted CAR-T lentiviral vector drug)

atezolizumab (Tecentriq, Atezolizumab [TECENTRIQ])

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

HCB101 (HCB101)

atezolizumab (Tecentriq, Tislelizumab，atezolizumab or sugemalimab)

Amivantamab + FOLFIRI (Amivantamab + FOLFIRI)

Anti-CD56 CAR T (Anti-CD56 CAR T)

Amcenestrant + Letrozole (Amcenestrant + Letrozole)

Universal Donor Expanded TGF-beta-imprinted NK Cells (Universal Donor Expanded TGF-beta-imprinted NK Cells)

trastuzumab (Herceptin, Patritumab and Trastuzumab)

pembrolizumab (Keytruda, SD-101 + Pembrolizumab)

CD123 targeted CAR-NK cells (CD123 targeted CAR-NK cells)

YSCH-01 (YSCH-01)

pd-1 and DC-NK cells (pd-1 and DC-NK cells)

FT-003 (FT-003)

ARI-0001 (ARI-0001)

CMV-TCR-T cells (CMV-TCR-T cells)

KRAS TCR-Transduced PBL (KRAS TCR-Transduced PBL)

5-hydroxytryptamine subtype 3 receptor antagonist (5-hydroxytryptamine subtype 3 receptor antagonist)